Traders Purchase High Volume of Maravai LifeSciences Put Options (NASDAQ:MRVI)

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) saw unusually large options trading on Wednesday. Investors acquired 1,002 put options on the stock. This is an increase of approximately 1,791% compared to the average daily volume of 53 put options.

Maravai LifeSciences Trading Down 15.0 %

Shares of NASDAQ:MRVI traded down $0.78 during midday trading on Friday, hitting $4.42. 4,075,846 shares of the stock traded hands, compared to its average volume of 2,273,125. The company has a quick ratio of 9.28, a current ratio of 10.74 and a debt-to-equity ratio of 0.89. The stock has a market capitalization of $1.11 billion, a PE ratio of -2.88 and a beta of 0.02. Maravai LifeSciences has a one year low of $4.39 and a one year high of $11.56. The business’s 50 day moving average is $7.85 and its two-hundred day moving average is $8.44.

Analyst Ratings Changes

Several equities analysts recently commented on the stock. William Blair reaffirmed a “market perform” rating on shares of Maravai LifeSciences in a research note on Friday, November 8th. Wolfe Research started coverage on Maravai LifeSciences in a research report on Thursday. They issued a “peer perform” rating on the stock. UBS Group boosted their target price on Maravai LifeSciences from $8.50 to $11.00 and gave the stock a “neutral” rating in a research report on Thursday, August 8th. Robert W. Baird lowered their price target on Maravai LifeSciences from $10.00 to $9.00 and set an “outperform” rating on the stock in a report on Friday, November 8th. Finally, Morgan Stanley cut shares of Maravai LifeSciences from an “overweight” rating to an “equal weight” rating and decreased their price objective for the stock from $11.00 to $10.00 in a research report on Tuesday, August 13th. Five investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $10.33.

Insider Buying and Selling

In related news, insider Carl Hull acquired 175,000 shares of the company’s stock in a transaction that occurred on Monday, November 11th. The shares were acquired at an average price of $5.64 per share, with a total value of $987,000.00. Following the acquisition, the insider now owns 175,000 shares of the company’s stock, valued at approximately $987,000. This trade represents a ∞ increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 0.63% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Maravai LifeSciences

Institutional investors and hedge funds have recently bought and sold shares of the business. GAMMA Investing LLC lifted its stake in Maravai LifeSciences by 310.2% in the second quarter. GAMMA Investing LLC now owns 3,585 shares of the company’s stock worth $26,000 after acquiring an additional 2,711 shares during the period. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Maravai LifeSciences in the 2nd quarter worth about $32,000. Headlands Technologies LLC bought a new stake in shares of Maravai LifeSciences during the 1st quarter valued at about $42,000. Blue Trust Inc. purchased a new position in shares of Maravai LifeSciences during the second quarter valued at about $44,000. Finally, Venturi Wealth Management LLC bought a new position in Maravai LifeSciences in the third quarter worth about $47,000. Hedge funds and other institutional investors own 50.25% of the company’s stock.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.